Shanghai Journal of Stomatology ›› 2014, Vol. 23 ›› Issue (1): 117-119.

• Clinical Reports • Previous Articles     Next Articles

Preliminary report of botulinum toxin type A injection at trigger point for treatment of trigeminal neuralgia:experiences of 16 cases

WANG Shuang-yi, YUE-jin, XU Yao-xiang, XUE Ling-fa, XIAO Wen-lin, ZHANG Chun-yang   

  1. Department of Stomatology, the Affiliated Hospital of Medical College, Qingdao University. Qingdao 266555, Shandong Province, China
  • Received:2013-06-03 Revised:2013-08-10 Online:2014-02-20 Published:2014-10-21

Abstract: PURPOSE: To investigate the effects of injection of botulium toxin type A at trigger point for treatment of patients with primary trigeminal neuralgia. METHODS: Sixteen patients with primary Trigeminal Neuralgia were treated with injection of botulium toxin type A. Visual analog scores(VAS) at 1 week, 2 weeks, 1 month, 3months and 6 months after treatment and Barrow Neurological Institute (BNI) pain evaluation criteria were utilized to measure the degree of pain. The data was analyzed with SPSS 10.0 software package. RESULTS: The VAS score was 9.12±0.65 before botulium toxin type A injection while the scores were 2.8±1.36, 2.2±1.26, 1.3±1.45, 1.3±1.45 and 1.2±2.52 at 1 week, 2 weeks, 1 month,3 months and 6 months after treatment. There was significant difference in VAS compared with before treatment. VAS score was lower and stable at 1 month, 3 months and 6 months after treatment, but no significant difference was found at 1-week and 2-week after treatment. BNI evaluation results showed good therapeutic effect 1 week after treatment, while the best therapeutic effect was noted 1-3 months after treatment. 6 months later, 1 patient had recurrence and 11 patients had complete relief of pain. CONCLUSIONS: Botulium toxin type A injection is an effective way for treatment of patients with primary trigeminal neuralgia.

Key words: Botulium toxin type A, Trigeminal neuralgia, Injection therapy

CLC Number: